Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate (CLVT) said its subsidiary accepted $75 million of its 2028 secured notes for purchase after a cash tender offer. Clarivate Science Holdings received $665.198 million in valid tenders against the $75 million offer cap; $825 million was outstanding before the offer. The final proration factor was 11.3%.
The offer expired on September 23, 2026, and all conditions were satisfied or waived by then. Consideration is $975.15 per $1,000 principal amount accepted. Holders of accepted notes will also receive an accrued coupon payment on the September 25 settlement date. Notes tendered but not accepted will be returned promptly.
Clarivate (CLVT) priced its subsidiary’s cash tender offer for 2028 secured notes at $975.15 per $1,000 of accepted principal.
Clarivate Science Holdings is offering to purchase up to $75 million in principal of its 3.875% senior secured notes due 2028; $825 million is outstanding. The price reflects a 4.864% reference yield determined at 2:00 p.m. New York City time on September 23, 2026, and a 50-basis-point fixed spread. Holders whose notes are accepted will also receive accrued and unpaid interest to, but excluding, the settlement date. The offer expires at 5:00 p.m. New York City time on September 23 unless extended or terminated earlier. Notes may be withdrawn until that time, subject to the offer terms. Settlement is expected September 25. Purchases remain subject to offer conditions and possible proration. The subsidiary may change or remove the purchase cap before expiration.
Clarivate (CLVT) will report its third quarter 2026 financial results before the market opens on Tuesday, November 3, 2026.
The earnings press release and supplement will be available on the Clarivate investor website at https://ir.clarivate.com. The company will host a conference call and live webcast at 8:30 AM Eastern Time the same day to review the results, and the webcast may include forward-looking information.
The live webcast is accessible via the investor relations section of the website or directly at https://events.q4inc.com/attendee/388781202. U.S. participants can join the live audio by calling 833-461-5787, and international participants can call +1 585-542-9983 using conference ID 388 781 202. A replay of the webcast will be available on the investor website about two hours after the call and will remain accessible for one year.
Clarivate (CLVT) has launched a cash tender offer for up to $75,000,000 aggregate principal amount of its subsidiary Clarivate Science Holdings Corporation's 3.875% Senior Secured Notes due 2028.
The notes have $825,000,000 aggregate principal outstanding and are identified by specified 144A and Reg S CUSIP/ISINs. The Total Consideration per $1,000 principal amount will be set using a fixed spread of 50 basis points over the yield of the 4.125% U.S. Treasury due June 30, 2028, as quoted at 2:00 p.m. New York City time on September 23, 2026, the Price Determination Date. The offer expires at 5:00 p.m. New York City time on September 23, 2026, with settlement expected on September 25, 2026, and includes payment of accrued and unpaid interest on accepted notes.
Clarivate (CLVT) has named 22 researchers as Citation Laureates 2026, recognizing Nobel-class scientific and economic discoveries across physiology or medicine, physics, chemistry and economics.
The honorees include pioneers behind GLP-1 biology and medicines for diabetes and obesity, optical coherence tomography, precision gene editing, advanced OLED technologies, and the economics of the digital economy and monetary policy. They are affiliated with institutions in seven countries/regions, with 16 based in the United States. Since 2002, 89 past Citation Laureates have later received Nobel Prizes. Candidates are drawn from the fewer than 0.02% of Web of Science papers cited more than 2,000 times.
Clarivate (NYSE:CLVT) announced expanded agentic AI capabilities across its Cortellis portfolio to support life sciences organizations throughout the drug development lifecycle. The enhancements embed AI directly into existing R&D workflows to reduce manual effort, navigate complex data and enable faster, more informed scientific and strategic decisions.
According to Clarivate, new capabilities in Cortellis Drug Discovery Intelligence, OFF-X and Cortellis Competitive Intelligence help teams accelerate discovery evaluations, advance proactive safety assessment and strengthen competitive and portfolio strategy. The platform combines proprietary data, expert curation and embedded AI to transform research, safety and market analysis into actionable intelligence.
Clarivate (NYSE: CLVT) appointed Michael Easton as Executive Vice President and Chief Financial Officer, effective August 8, 2026. He succeeds Jonathan Collins, who is stepping down as CFO to pursue another opportunity.
Easton has over 25 years of finance, accounting and operations experience and most recently served as Senior Vice President and Chief Accounting Officer, overseeing Clarivate’s core financial reporting and planning functions. As CFO, he will focus on accelerating growth, improving profitability, strengthening free cash flow generation and maintaining disciplined capital allocation. Clarivate also reported its second quarter 2026 financial results in a separate release and will host a webcast at 9:30 AM Eastern Time to review them.
Clarivate (NYSE: CLVT) reported second quarter 2026 revenues of $587.3 million, down 5.5% year over year, with organic revenues declining 1.5% as 0.7% organic subscription growth was offset by weaker transactional activity. Net loss widened to $268.6 million ($0.42/share), primarily due to a $221.7 million non-cash goodwill impairment.
Adjusted net income was $123.1 million and Adjusted EBITDA $247.2 million. For the first half, revenue was $1.17 billion, Adjusted EBITDA $488.4 million, and free cash flow $122.9 million. Total debt fell by $218.4 million to $4.25 billion. Clarivate highlighted progress on its Value Creation Plan, the previously announced Life Sciences & Healthcare divestiture, and reaffirmed its 2026 outlook, including revenue of $2.30–$2.42 billion and Adjusted EBITDA of $980 million–$1.04 billion.
Clarivate (NYSE: CLVT) announced that its AI-powered trademark risk assessment solution RiskMark has won the 2026 CODiE Award for Best AI Tool for Lawyers. Launched in 2025, RiskMark uses predictive and generative AI on 172.5 million trademark records and over five million decisions to help legal professionals evaluate trademark confusion and risk quickly and reliably.
Clarivate (NYSE: CLVT) is providing AI-assisted image search technology to power a new image search capability in the U.S. Patent and Trademark Office’s TM Search trademark system. Users can now upload images and compare them against the U.S. trademark register to help identify visually similar existing marks, improving search efficiency and result quality.